Isis Pharmaceuticals (ISIS) 54.65 $ISIS Retinitis

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Isis Pharmaceuticals (ISIS) 54.65 $ISIS

Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles
M2 - Tue Jul 28, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vhmx/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - BioDiem Ltd - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - R-Tech Ueno, Ltd. - ReNeuron Group Plc - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AMRS-001 - Antibodies to Antagonize IL-6 for Retinitis - BDM-E - BNP-RP - CB-11 - ECL-1 - emixustat hydrochloride - FIB-111 - Gene Therapy for Glaucoma and Retinitis Pigmentosa - Gene Therapy for Ocular Diseases - Gene Therapy for Ophthalmology - Gene Therapy for Retinitis Pigmentosa - Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - GS-020 - GT-038 - ISISRHO-2.5Rx - KIRA-6 - NT-501 - OCU-100 - PRO-015 - proinsulin human SR - QLT-091001 - Recombinant Human Nerve Growth Factor - ReN-003 - Retinal Progenitor Cells for Ophthalmological Disorders - RGX-321 - RST-001 - SAR-421869 - SHP-630 - Small Molecule for Retinitis Pigmentosa - Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Small Molecules for CNS Disorders and Ophthalmology - Small Molecules for Retinitis Pigmentosa - Small Molecules for Retinitis Pigmentosa For more information visit http://www.researchandmarkets.com/research/p6vhmx/retinitis
OCAT: 4.29 (-0.34), QLTI: 3.91 (+0.01), ISIS: 54.65 (+0.97), ONCE: 62.97 (+1.01), SHPG: 263.45 (+4.34), CLBS: 1.80 (+0.06)

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call
PR Newswire - Tue Jul 28, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, August 4 at 11:30 a.m. Eastern Time to discuss its second quarter 2015 financial results and report on pipeline and business progress.
ISIS: 54.65 (+0.97)

'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.38 (+0.18), MMM: 151.46 (+2.75), BIIB: 317.46 (+8.03), ISIS: 54.65 (+0.97), MDSO: 53.99 (+1.16), COP: 52.75 (+2.10), SNDK: 61.15 (-0.01)

Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.38 (+0.18), MMM: 151.46 (+2.75), AMZN: 525.82 (-5.59), BIIB: 317.46 (+8.03), MDLZ: 42.82 (+0.79), EA: 72.00 (+0.78), SNA: 160.73 (+3.64), NKE: 113.47 (+1.74), MDSO: 53.99 (+1.16), FB: 95.19 (+1.02), FCX: 12.46 (+1.09), COP: 52.75 (+2.10), DIS: 118.58 (+0.33), NFLX: 107.60 (+1.17), ISIS: 54.65 (+0.97), QLIK: 40.67 (+0.73), KHC: 78.30 (+0.92), GOOGL: 658.91 (+0.64), ULTA: 166.04 (-0.35), CMCSA: 62.22 (+1.11), GIS: 57.35 (+0.39), SNDK: 61.15 (-0.01)

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 159.12 (-0.37), BIIB: 317.46 (+8.03), NBIX: 52.12 (+2.78), ISIS: 54.65 (+0.97), SRPT: 32.35 (+0.35), RCPT: 227.70 (+0.61)

ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy
PR Newswire - Mon Jul 27, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today encouraging preliminary results from an investigator-sponsored study in patients with transthyretin amyloid-related cardiomyopathy that was presented yesterday by Dr. Merrill Benson at the 20th World Congress on Heart Disease (WCHD) in Vancouver, Canada.
ISIS: 54.65 (+0.97)

Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
PR Newswire - Wed Jul 22, 6:17PM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet has published clinical data evaluating ISIS-APO(a)Rx in healthy volunteers with elevated lipoprotein(a) or Lp(a). An accompanying editorial was also published. ISIS-APO(a)Rx is a Generation 2.0+ antisense drug that is part of Isis' lipid franchise, which is being developed and commercialized by Akcea Therapeutics, Isis' wholly owned subsidiary.
ISIS: 54.65 (+0.97)

Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 2:20PM CDT
Isis Pharmaceuticals' (ISIS) Huntington's disease candidate, ISIS-HTTRx, moves into a phase I/IIa study; earns a milestone payment of $22 million from Roche.
BIIB: 317.46 (+8.03), ISIS: 54.65 (+0.97), AMAG: 66.69 (+1.62)

Critical Alerts For Isis Pharmaceuticals, NXP Semiconductors, Transocean, Microsoft and Boeing Released By InvestorsObserver
PR Newswire - Wed Jul 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ISIS, NXPI, RIG, MSFT and BA.
RIG: 14.02 (+0.91), ISIS: 54.65 (+0.97), NXPI: 91.57 (+3.35), BA: 141.75 (+0.72), MSFT: 45.41 (+0.06)

Isis Pharmaceuticals begins Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease
M2 - Wed Jul 22, 5:13AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) disclosed on Tuesday the launch of a Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease (HD), a rare genetic neurological disease in which patients experience deterioration of both mental abilities and physical control.
ISIS: 54.65 (+0.97)

Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 98.98 (+0.70), ISIS: 54.65 (+0.97), GILD: 112.91 (+2.37), PFE: 35.17 (+0.83), SGMO: 9.17 (+0.30), BMY: 64.44 (+0.14), NVS: 102.59 (+1.05), XLRN: 29.05 (+0.55)

Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
PR Newswire - Tue Jul 21, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that it has initiated a Phase 1/2a clinical study of ISIS-HTTRx in patients with Huntington's disease (HD). ISIS-HTTRx is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein responsible for HD. HD is a rare genetic neurological disease in which patients experience deterioration of both mental abilities and physical control. Presently, there are no disease-modifying treatments for HD, with current therapies focused only on treating disease symptoms. ISIS-HTTRx has been granted orphan drug designation by the European Medicines Agency for the treatment of patients with HD. Orphan drug designation is granted to products designed to diagnose, prevent or treat life-threatening or very serious conditions that affect not more than five in 10,000 persons in the European Union.
ISIS: 54.65 (+0.97)

Inotek Pharmaceuticals Corporation Appoints Claudine Prowse, Ph.D. as Vice President, Strategy and Investor Relations Officer
Business Wire - Mon Jul 20, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the appointment of Claudine Prowse, Ph.D., as Vice President, Strategy and Investor Relations. Dr. Prowse's responsibilities will include defining corporate strategy to expand business opportunities, corporate communications and investor relations, and interfacing with key external business and investor constituents. She will report directly to David P. Southwell, President and Chief Executive Officer, and serve as a member of the Inotek management team.
ISIS: 54.65 (+0.97), ITEK: 17.98 (+1.22)

'Mad Money' Lightning Round: Buy General Mills, Not B&G Foods
at The Street - Fri Jul 17, 5:00AM CDT
Cramer says TravelCenters of America is a winner, Skyworks Solutions can go higher but he doesn't want to own Apache.
KMI: 35.87 (+0.65), ABB: 19.87 (+0.19), SWKS: 96.00 (+2.51), ISIS: 54.65 (+0.97), BGS: 29.17 (+0.18), VLY: 10.07 (-0.01), APA: 46.95 (+2.44), GIS: 57.35 (+0.39), TA: 15.50 (+0.31)

Jim Cramer's 'Mad Money' Recap: Where Are the Market Winners? Right Here
at The Street - Thu Jul 16, 7:19PM CDT
Cramer says to watch some unfamiliar names in technology plus the bank stocks.
KMI: 35.87 (+0.65), SWKS: 96.00 (+2.51), VLY: 10.07 (-0.01), KEY: 14.81 (+0.03), INTC: 28.94 (+0.59), NFLX: 107.59 (+1.16), ABB: 19.87 (+0.19), NOW: 78.29 (+1.95), BGS: 29.17 (+0.18), ISIS: 54.65 (+0.97), APA: 46.95 (+2.44), DPZ: 111.67 (+0.36), DATA: 126.28 (+1.28), MSFT: 45.41 (+0.06), GIS: 57.35 (+0.39), TA: 15.50 (+0.31)

Isis Pharmaceuticals Up on Milestone Payment from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 3:30PM CDT
Isis Pharmaceuticals (ISIS) earned a milestone payment of $2.15 million from Biogen for the advancement of ISIS-SMNRx in children with spinal muscular atrophy.
BIIB: 317.46 (+8.03), ISIS: 54.65 (+0.97), EBIO: 2.75 (-0.06), AMAG: 66.69 (+1.62)

Isis Pharmaceuticals Rises 4.67% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 14, 4:27PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $53.50 to a high of $56.64. Yesterday, the shares gained 4.7%, which took the trading range above the 3-day high of $54.87 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 54.65 (+0.97)

8 Companies With Accidentally Disastrous Names
at The Street - Tue Jul 14, 8:49AM CDT
From Isis Pharmaceuticals to Kony Inc. to Grexit, these companies have had to deal with grim news events casting a cloud over their names.
ISIS: 54.65 (+0.97)

Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy
PR Newswire - Tue Jul 14, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.15 million milestone payment from Biogen related to advancing the ongoing pivotal Phase 3 study (CHERISH) evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). To date, Isis has generated more than $120 million in payments from Biogen related to the development of ISIS-SMNRx.
ISIS: 54.65 (+0.97)

Muscular Dystrophy Pipeline Report 2015 - 21 Companies & 47 Drug Profiles
M2 - Fri Jul 10, 3:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89rk9v/muscular) has announced the addition of the "Muscular Dystrophy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - aTyr Pharma, Inc. - Benitec Biopharma Limited - Bioblast Pharma Ltd. - BioMarin Pharmaceutical Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Fate Therapeutics, Inc. - Genethon - Genzyme Corporation - Isis Pharmaceuticals, Inc. - Marina Biotech, Inc. - Novogen Limited - PolyNovo Limited - Prothelia, Inc. - SanBio, Inc. - Santhera Pharmaceuticals Holding AG - Sarepta Therapeutics, Inc. - Selecta Biosciences, Inc. - Takeda Pharmaceutical Company Limited - Valentia Biopharma S.L. For more information visit http://www.researchandmarkets.com/research/89rk9v/muscular
FATE: 7.50 (+0.07), BMRN: 145.50 (+1.18), ISIS: 54.65 (+0.97), SRPT: 32.35 (+0.35), XLRN: 29.05 (+0.55)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 188

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 164

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

New York Court Upholds Healthcare Rights for Retirees

Updated Category News Views 94

New York Court of Appeals Decision on Retiree Healthcare Rights In a landmark ruling, the New York Court of Appeals determined that the city is required to cover the total cost of the health insurance plans chosen by its retirees. This decision represents a significant win for over 250,000 retired workers and their families seeking to maintain their healthcare benefits....

Continue Reading
Corning's Strategic Path Amid AI Trends and Market Challenges

Updated Category News Views 1824

Corning Incorporated (NYSE: GLW) hit a crossroads back in 2024 as it tried to balance rising AI trends with challenges lurking in traditional markets. Renowned for its expertise in materials science, particularly specialty glass and optical physics, Corning was looking to leverage these trends while facing stiff competition and economic uncertainties. Quarterly...

Continue Reading
Innovating the Future: The Inaugural Global Quantum Forum

Updated Category News Views 274

Inaugural Global Quantum Forum Set to Launch During TechChicago Week The upcoming Global Quantum Forum promises to be a landmark event for the quantum industry, coinciding with the much-anticipated TechChicago Week. This two-day conference is positioned to take place in an exciting environment where innovation meets collaboration. With over 70 distinguished speakers,...

Continue Reading
Oil Prices React to US Supply and Rising Geopolitical Risks

Updated Category News Views 83

Oil Market Overview: Supply Dynamics and Geopolitical Tensions As oil prices faced a dip recently, analysts found that U.S. supply levels play a significant role in shaping market trends. The weekly report reflecting increased U.S. crude and gasoline stocks was a key factor influencing the downturn. Insights on Current Oil Price Performance Brent crude futures for January...

Continue Reading
Senator McConnell's Recent Stock Purchase Insights and Implications

Updated Category News Views 160

Insights into Senator McConnell's Stock Purchase Recently, it has come to public attention that Senator A. Mitchell McConnell, Jr. has made a notable financial move by purchasing stock in Wells Fargo (NYSE: WFC). This purchase, reported to be valued between $1,001 and $15,000, is part of a pattern of trading activity that might have implications for investors and stock...

Continue Reading